According to a commentary, the evidence of high vaccine effectiveness, along with high vaccine uptake, should be reassuring to health authorities in other countries who are considering whether to introduce vaccine programmes against group B meningococcal disease (MenB). It notes that the cost-effectiveness analyses played a central part in the decision to introduce the vaccine in the UK; and to inform vaccination policies in other settings, additional epidemiological and cost-effectiveness studies are now needed to answer important remaining questions, including how differences in the age distribution of MenB cases, variation in the relative frequencies of disease-causing MenB strains, the potential impact of MenB vaccines on carriage among teenagers, and variation in the costs of vaccination programmes could affect the impact of MenB vaccines. It concludes that if the reductions in MenB disease observed among UK infants are sustained over time and replicated in other settings, then MenB vaccines could have a vital role in reducing the threat of meningococcal disease.